PDC*LINE PHARMA HAS BEEN SELECTED FOR AN ORAL PRESENTATION AT THE ANNUAL MEETING OF KOREAN CANCER ASSOCIATION
We are delighted to announce that we have been selected for an oral presentation at the International Session of the 50th Annual Meeting of Korean Cancer Association (KCA 2024)! PDC*line Pharma received the KCA International Abstract Award this year again!
The presentation has been made today by Felicia Kim in Seoul (Korea) June 20th 2024.
Title of the presentation: preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 as a first-line therapy in patients with stage IV non-small cell lung cancer based on the first interim analysis of the initial 19 evaluable patients.
After the AACR, CIMT and EIF annual conferences, it is the fourth oral presentation of our clinical results in an international and prestigious medical/scientific conference this year!
About Korean Cancer Association (KCA):
Established in 1974, the Korean Cancer Association is the most authoritative scientific society dedicated to advancing the field of oncology in Korea. KCA represents over 2,300 members from 150 institutes, including clinical oncologists and basic scientists, and it has consistently expanded its academic prominence and impact across Asia.
KCA is a member of the Union for International Cancer Control's (UICC) and serves as a council member of the Asian Oncology Society (AOS).
Additionally, KCA publishes a SCI indexed journal called Cancer Research and Treatment(CRT) and holds an annual meeting in conjunction with the International Cancer Conference.
